The psoriasis drug market is fiercely competitive, and strongly held by large pharmaceutical...
- Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
- Allergan assesses brazikumab in two clinical programmes for IBD
- AstraZeneca reports negative top-line results from TULIP 1 trial
- Arrowhead concludes dosing in Phase I ARO-AAT trial
- Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
Blincyto® (blinatumomab) for the Treatment of B-cell Precursor Acute Lymphoblastic Leukaemia
Blincyto® (blinatumomab) is a monoclonal antibody indicated as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.
Tradjenta Indicated for the Treatment of Type II Diabetes
Linagliptin (BI-1356), which is being marketed under the trade name Tradjenta®, is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor drug for the treatment of type 2 diabetes.
Vedanta Biosciences initiates Phase I study of VE202 to treat IBD
Vedanta Biosciences has initiated a Phase I clinical study of its live biotherapeutic product (LBP) candidate VE202 for the treatment of inflammatory bowel disease (IBD)
Generex and NSABP to manage Phase II clinical trial of keytruda
Generex Biotechnology will manage a Phase II clinical trial of pembrolizumab (keytruda) for the treatment of patients with metastatic triple negative breast cancer after signing an agreement with the NSABP Foundation.
Bristol-Myers Squibb’s drug trial fails to meet primary endpoint
Bristol-Myers Squibb has reported that the Phase III CheckMate -451 study failed to meet its primary endpoint of overall survival (OS) with opdivo (nivolumab) as a maintenance therapy in patients with extensive-stage small cell lung cancer (SCLC) after completion of first-line chemotherapy.
Actinogen enrols final patient in Phase II trial of xanamem
Actinogen Medical has enrolled the final patient into its Phase II clinical trial to evaluate the safety, tolerability and efficacy of xanamem for the treatment of patients with mild Alzheimer’s disease.
Data from NIH-funded trial offers hope for gonorrhoea treatment
A Phase II clinical trial funded by the UK's National Institutes of Health (NIH) has shown that new antibiotic candidate, zoliflodacin, could cure uncomplicated gonorrhoea in the majority of patients.
Stabilisation, Isolation, and Characterisation of Circulating Tumour Cells
A combination of technologies from French company ScreenCell and British company Caltag Medsystems has allowed for improved analysis of single circulating tumour cells.
Orthotopic and Metastasis Models for Preclinical Efficacy Testing of Novel Cancer Drugs
Lack of efficacy is one of the major causes of attrition in the clinical development of new compounds to treat cancer.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.